Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape

  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gel, Bernat|||0000-0001-8878-349X
  • Rosas, Inma|||0000-0003-4238-0227
  • Tornero, Eva
  • Santín, Sheila
  • Pluvinet, Raquel
  • Velasco, Juan
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Perucho, Manuel|||0000-0002-2169-2662
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Navarro, Matilde
  • Brunet, Joan|||0000-0003-1945-3512
  • Pineda, Marta|||0000-0002-5403-5845
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Serra, Eduard|||0000-0003-2895-9857
We wanted to implement an NGS strategy to globally analyze hereditary cancer with diagnostic quality while retaining the same degree of understanding and control we had in pre-NGS strategies. To do this, we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes. We improved bait design, tested different NGS platforms and created a clinically driven custom data analysis pipeline. The I2HCP panel was developed using a training set of hereditary colorectal cancer, hereditary breast and ovarian cancer and neurofibromatosis patients and reached an accuracy, analytical sensitivity and specificity greater than 99%, which was maintained in a validation set. I2HCP changed our diagnostic approach, involving clinicians and a genetic diagnostics team from panel design to reporting. The new strategy improved diagnostic sensitivity, solved uncertain clinical diagnoses and identified mutations in new genes. We assessed the genetic variation in the complete set of hereditary cancer genes, revealing a complex variation landscape that coexists with the disease-causing mutation. We developed, validated and implemented a custom NGS-based strategy for hereditary cancer diagnostics that improved our previous workflows. Additionally, the existence of a rich genetic variation in hereditary cancer genes favors the use of this panel to investigate their role in cancer risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data

  • Gel, Bernat|||0000-0001-8878-349X
  • Serra, Eduard|||0000-0003-2895-9857
Abstract. Motivation: Data visualization is a crucial tool for data Exploration, analysis and interpretation. For the visualization of genomic data there lacks a tool to create customizable non-circular plots of whole genomes from any species. Results: We have developed karyoploteR, an R/Bioconductor package to create linear chromosomal representations of any genome with genomic annotations and experimental data plotted along them. Plot creation process is inspired in R base graphics, with a main function creating karyoplots with no data and multiple additional functions, including custom functions written by the end-user, adding data and other graphical elements. This approach allows the creation of highly customizable plots from arbitrary data with complete freedomon data positioning and representation. Availability and implementation: karyoploteR is released under Artistic-2.0 License. Source code and documentation are freely available through Bioconductor http://www.bioconductor.org/pack ages/karyoploteR) and at the examples and tutorial page at https://bernatgel.gitHub.io/karyoploter_ tutorial. Contact: bgel@igtp.cat.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT), initial results from an international prospective study

  • Bancroft, Elizabeth|||0000-0002-5482-5660
  • Page, Elizabeth C.
  • Brook, Mark N.|||0000-0002-8969-2378
  • Thomas, Sarah
  • Taylor, Natalie
  • Pope, Jennifer
  • McHugh, Jana
  • Jones, Ann-Britt
  • Karlsson, Questa
  • Merson, Susan
  • Ong, Kai Ren
  • Hoffman, Jonathan
  • Huber, Camilla
  • Maehle, Lovise
  • Grindedal, Eli Marie
  • Stormorken, Astrid
  • Evans, Gareth|||0000-0002-8482-5784
  • Rothwell, Jeanette
  • Lalloo, Fiona
  • Brady, Angela F.
  • Bartlett, Marion
  • Snape, Katie
  • Hanson, Helen
  • James, Paul|||0000-0002-4361-4657
  • McKinley, Joanne
  • Mascarenhas, Lyon
  • Syngal, Sapna
  • Ukaegbu, Chinedu
  • Side, Lucy
  • Thomas, Tessy
  • Barwell, Julian
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Izatt, Louise|||0000-0003-1258-4843
  • Suri, Mohnish|||0000-0001-9037-701X
  • Macrae, Finlay A.
  • Poplawski, Nicola
  • Chen-Shtoyerman, Rakefet|||0000-0002-5055-5907
  • Ahmed, Munaza
  • Musgrave, Hannah
  • Nicolai, Nicola|||0000-0002-5718-2699
  • Greenhalgh, Lynn
  • Brewer, Carole
  • Pachter, Nicholas
  • Spigelman, Allan D.
  • Azzabi, Ashraf
  • Helfand, Brian T.
  • Halliday, Dorothy
  • Buys, Saundra|||0000-0003-4120-5697
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Donaldson, Alan|||0000-0001-9193-4172
  • Cooney, Kathleen A.
  • Harris, Marion
  • McGrath, John
  • Davidson, Rosemarie
  • Taylor, Amy
  • Cooke, Peter
  • Myhill, Kathryn
  • Hogben, Matthew
  • Aaronson, Neil K.
  • Ardern-Jones, Audrey
  • Bangma, Chris H.
  • Castro, Elena|||0000-0002-3691-6454
  • Dearnaley, David|||0000-0002-3954-2806
  • Dias, Alexander
  • Dudderidge, Tim|||0000-0001-6373-3613
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Green, Kate
  • Eyfjord, Jorunn
  • Falconer, Alison
  • Foster, Christopher S.
  • Gronberg, Henrik
  • Hamdy, Freddie C.|||0000-0003-2627-2154
  • Johannsson, Oskar
  • Khoo, Vincent
  • Lilja, Hans|||0000-0001-5871-7846
  • Lindeman, Geoffrey J.|||0000-0001-9386-2416
  • Lubinski, Jan|||0000-0003-2931-3003
  • Axcrona, Karol|||0000-0002-5011-0107
  • Mikropoulos, Christos|||0000-0001-8070-2851
  • Mitra, Anita V.
  • Moynihan, Clare
  • Ni Raghallaigh, Holly
  • Rennert, Gad|||0000-0002-8512-068X
  • Collier, Rebecca
  • Offman, Judith|||0000-0001-5604-1635
  • Kote-Jarai, Zsofia|||0000-0002-6329-5155
  • Eeles, Rosalind|||0000-0002-3698-6241
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered with , , and is now closed to accrual. Between Sept 28, 2012, and March 1, 2020, 828 men were recruited (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6 ] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6 ]), and in order to boost the sample size for the non-carrier control groups, we randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts. Men were predominantly of European ancestry (899 [93%] of 953 with available data), with a mean age of 52·8 years (SD 8·3). Within the first screening round, 56 (6%) men had a PSA concentration of more than 3·0 ng/mL and 35 (4%) biopsies were done. The overall incidence of prostate cancer was 1·9% (18 of 962; 95% CI 1·1-2·9). The incidence among MSH2 carriers was 4·3% (13 of 305; 95% CI 2·3-7·2), MSH2 non-carrier controls was 0·5% (one of 210; 0·0-2·6), MSH6 carriers was 3·0% (four of 135; 0·8-7·4), and none were detected among the MLH1 carriers, MLH1 non-carrier controls, and MSH6 non-carrier controls. Prostate cancer incidence, using a PSA threshold of higher than 3·0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4·3% vs 0·5%; p=0·011) and MSH6 carriers than MSH6 non-carrier controls (3·0% vs 0%; p=0·034). The overall positive predictive value of biopsy using a PSA threshold of 3·0 ng/mL was 51·4% (95% CI 34·0-68·6), and the overall positive predictive value of a PSA threshold of 3·0 ng/mL was 32·1% (20·3-46·0). After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer compared with age-matched non-carrier controls. These findings support the use of targeted PSA screening in these men to identify those with clinically significant prostate cancer. Further annual screening rounds will need to confirm these findings.